Historical ilmn News Stories
Illumina Insider Sells $57M in Stock as Company Prepares to Rejoin S&P 500
An Illumina (NASDAQ: ILMN) insider sold $57 million in shares as the company gets set to rejoin the S&P 500 on September 21, 2026 — stock dipped in response.
Roche Launches AXELIOS 1, Challenging Illumina’s Dominance in Gene Sequencing Market
Roche unveiled the AXELIOS 1 sequencing platform in late June, signaling the first credible challenge to Illumina’s ~70% NGS market share.
Asset Managers Increase Stakes in Illumina Amid Patent Ruling Uncertainty
Several institutional investors disclosed new or expanded positions in Illumina this week, as a German patent ruling casts uncertainty over its sequencing business.
Illumina's Stock Performance Amidst Analyst Upgrades and Institutional Movements
Analyzing Illumina's stock dynamics influenced by recent analyst upgrades and institutional investment shifts.
Illumina's Stock Experiences Volatility Amid Analyst Upgrades and Institutional Sell-Offs
Illumina's stock sees fluctuations due to analyst upgrades and institutional sell-offs.
Illumina's Stock Hits 52-Week High Following Analyst Upgrade
Illumina's stock reaches new high after analyst raises price target.
Illumina's Market Position Challenged by Roche's New Sequencing Technology
Roche's Axelios system intensifies competition in genetic sequencing.
Illumina Faces Intensified Competition Amidst Market Innovations
Illumina confronts new challenges as competitors introduce advanced sequencing technologies.
Illumina Rally: TruPath & NovaSeq X Drive Momentum.
Illumina (ILMN) surged after AGBT 2026 announcements introducing TruPath Genome and NovaSeq X upgrades. The innovations boosted investor confidence, produced a near-term stock rally, and prompted strategic portfolio moves such as ARK Invest trimming exposure. This article breaks down the technical advances, market reaction, and what investors should watch next.
Illumina Surge: RS Upgrade Sparks Trading Rally Q1
Illumina (NASDAQ: ILMN) saw a meaningful RS Rating upgrade and a strong trading bounce in mid‑February 2026. Elevated volume and price gains indicate renewed investor attention, while technical signals suggest cautious, tactical buying rather than aggressive entry at current levels.
Illumina Slides After Weak 2026 Guidance China Hit
Illumina shares fell sharply after a cautious 2026 outlook and ongoing China instrument approval delays. Analyst downgrades and elevated trading volumes compounded the selloff even as SomaLogic integration and multi‑omics initiatives remain longer‑term positives.
Illumina Faces Selloff Medicare Backs TruSight Test
Ilumina (ILMN) slipped in early February amid investor caution despite firm financials and strategic progress. Key drivers this week: final FY2025 results that confirmed revenue and cash generation; Medicare reimbursement for TruSight Oncology Comprehensive at $2,989.55 per test; completion of the SomaLogic acquisition and launch of a Billion Cell Atlas data product; easing of Chinese export restrictions but continued regulatory approvals required; and renewed competition from MGI’s high-speed sequencers. These concrete developments create a clearer near-term revenue runway while also highlighting competitive and geopolitical headwinds.
Illumina Unveils Billion Cell Atlas; ILMN Upside!!
Illumina announced the Billion Cell Atlas — a 1 billion single-cell CRISPR perturbation dataset (scaling toward 5 billion) with major pharma partners and integration into its DRAGEN/Connected Analytics stack. This platform-scale move strengthens Illumina’s data and analytics moat and has measurable near-term market sentiment uplift for ILMN.
Illumina's Billion Cell Atlas Boosts ILMN Outlook.
Illumina released preliminary Q4/FY2025 figures showing stabilized revenue and stronger ex‑China growth, while unveiling the Billion Cell Atlas and Connected Multiomics—major initiatives that expand its data and software footprint. These concrete moves shift Illumina toward an integrated sequencing-plus-cloud strategy ahead of its Feb. 5 earnings.
Illumina (ILMN): Billion Cell Atlas Spurs Q4
Illumina’s recent product launches — the Billion Cell Atlas and Connected Multiomics — and volatile share moves set the stage for a crucial Feb. 5 Q4/FY2025 earnings release. Investors should watch revenue mix, SomaLogic integration progress, and early adoption metrics for these strategic initiatives.
Illumina Surge: NovaSeq X, SomaLogic IntegrationQ1
Illumina (ILMN) staged a notable early‑January rally driven by renewed investor interest and optimism around NovaSeq X momentum and the pending SomaLogic acquisition. The stock moved toward its 52‑week high amid elevated volumes; near‑term catalysts include product adoption, consumables growth, and integration milestones.
Illumina BioInsight Boosts AI Sequencing Value Now
Illumina (ILMN) has shifted emphasis from hardware to data and AI with its BioInsight unit and an upcoming J.P. Morgan presentation that could provide fresh guidance or strategic detail. Early market reaction to BioInsight was positive; investors should watch conference disclosures and early adoption signals closely.
Illumina Rallies on MyOme Deal; ILMN Trade Spike Now
Illumina (ILMN) saw a mid‑December rally after announcing a strategic collaboration with MyOme—boosting volume and short‑term investor optimism against a backdrop of recent earnings strength.
Illumina Slides; MyOme Deal Signals Clinical Pivot
Illumina (ILMN) has slid in recent sessions while announcing a strategic investment and collaboration with MyOme to advance clinical trials and precision medicine applications. Short-term trading shows declining price and low volume, but the MyOme partnership points to expanded clinical focus that could alter Illumina's growth profile if trial outcomes validate projected healthcare savings.
Illumina Rally, Guidance Cut & MGI Threat Looms Q4
Illumina shares rose on renewed investor interest even as Q1 results prompted a trimmed full‑year outlook. Strategic partnerships in single‑cell and clinical sequencing, plus board appointments, offer offsets to headwinds from China restrictions and intensified competition from MGI’s new ultrafast sequencer. Investors should weigh short‑term sentiment against structural risks and execution catalysts.